Stock ALCLS CELLECTIS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Cellectis S.A.

Equities

ALCLS

FR0010425595

Market Closed - Euronext Paris
Other stock markets
 11:35:24 2024-04-30 am EDT 		After market 12:33:15 pm
2.435 EUR -0.61% Intraday chart for Cellectis S.A. 2.443 +0.33%
Apr. 29 Cellectis S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Apr. 29 Cellectis S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
European Earnings, Rate-hike Predictions Push French Stocks to Red
MT
Citigroup Adjusts Cellectis Price Target to $16 From $24, Maintains Buy Rating
MT
Oppenheimer Adjusts Cellectis Price Target to $13 From $16, Maintains Outperform Rating
MT
Goldman Sachs Adjusts Cellectis' Price Target to $2 from $3, Keeps Sell Rating
MT
Baird Upgrades Cellectis to Outperform From Neutral
MT
Barclays Lowers Cellectis S.A's Price Target to $7 From $9, Overweight Rating Maintained
MT
Wells Fargo Downgrades Cellectis to Equalweight From Overweight; Price Target is $16
MT
JMP Securities Starts Cellectis at Market Outperform With $20 Price Target
MT
CELLECTIS S A : Baird Downgrades Cellectis to Neutral from Outperform, Adjusts Price Target to $10 from $39
MT
CELLECTIS S A : Guggenheim Downgrades Cellectis to Neutral from Buy
MT
CELLECTIS S A : Baird Upgrades Cellectis to Outperform From Neutral, Adjusts Price Target to $39 From $23
MT
Cellectis S.A. and Pfizer Inc. Completes Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALCLS Stock
  4. News Cellectis S.A.
  5. Analyst Reco.